Explore the words cloud of the TiDrugArchitectures project. It provides you a very rough idea of what is the project "TiDrugArchitectures" about.
The following table provides information about the project.
Coordinator |
THE HEBREW UNIVERSITY OF JERUSALEM
Organization address contact info |
Coordinator Country | Israel [IL] |
Total cost | 2˙000˙000 € |
EC max contribution | 2˙000˙000 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2015-CoG |
Funding Scheme | ERC-COG |
Starting year | 2016 |
Duration (year-month-day) | from 2016-06-01 to 2021-05-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | THE HEBREW UNIVERSITY OF JERUSALEM | IL (JERUSALEM) | coordinator | 2˙000˙000.00 |
This proposal aims to develop custom designed anticancer therapeutic frameworks that are effective, stable, safe, and tumor targeted, based on the biocompatible TiIV metal. The Tshuva group has established that water stable phenolato TiIV complexes are especially effective as anticancer agents both in vitro and in vivo, with markedly reduced side effects. Optimal derivatives will be developed to combine activity, stability, and biological accessibility, by maintaining small steric bulk while incorporating strong binding donors and hydrophilicity. The mechanism of action will be investigated by chemical and biological methods, including analyzing bio-distribution, cellular pathways and targets, and interaction with bio-molecules. Specifically, the active metal centers will be linked to bioactive moieties through redox-sensitive S–S bonds to enable tumor targeting. Cell penetrating peptides will facilitate cellular penetration for redox-dependent release of the active species selectively in cancer cells; steroid moieties will direct selectivity to hormone-dependent cancer cell types. Since the combination of TiIV- with Pt-based drugs has shown synergistic effects, multi-active entities will include two or more metal centers, possibly also linked to a transport unit. In addition to linear conjugates, polymeric and dendritic assemblies, exploiting the enhanced permeability of cancer cells, will be constructed with theoretically unlimited options for targeted delivery of multiple active sites. Most importantly, flexible well-defined redox-sensitive cages, as well as rigid pH sensitive complex cages, constructed with customized 3D geometries, will enable specific targeting of any active compound or conjugate and selective dissociation only where desired. This study should yield superior anticancer drugs, while unraveling the mystery of their complex biochemistry, and will contribute to the development of novel chemical and medicinal research directions and applications.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Maya Miller, Edit Y. Tshuva Racemic vs. enantiopure inert Ti( iv ) complex of a single diaminotetrakis(phenolato) ligand in anticancer activity toward human drug-sensitive and -resistant cancer cell lines published pages: 39731-39734, ISSN: 2046-2069, DOI: 10.1039/c8ra08925f |
RSC Advances 8/69 | 2019-08-29 |
2018 |
Avia Tzubery, Naomi Melamed-Book, Edit Y. Tshuva Fluorescent antitumor titanium( iv ) salen complexes for cell imaging published pages: 3669-3673, ISSN: 1477-9226, DOI: 10.1039/c7dt04828a |
Dalton Transactions 47/11 | 2019-05-10 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIDRUGARCHITECTURES" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TIDRUGARCHITECTURES" are provided by the European Opendata Portal: CORDIS opendata.